CD38-targeted therapies in kidney disease: evidence maturity, disease-stage dependence, and biomarker-guided retreatment. [PDF]
Feng P, Yu X.
europepmc +1 more source
Abstract figure legend Intracellular pathways leading to Ca2+ signalling in pancreatic acinar cells, initiated by binding of ACh to muscarinic M3 receptors (M3Rs), gastrin‐releasing peptide (GRP) to bombesin type 2 receptors (BB2Rs) or cholecystokinin (CCK) to CCK1 receptors (CCK1Rs). M3R activation produces inositol 1,4,5‐trisphophate (IP3), releasing
Muhanad Salih +3 more
wiley +1 more source
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning. [PDF]
Yu L, Li C, Guo D, Cui S.
europepmc +1 more source
Microglial Labeling in Mouse Spinal Cord Injury: A Review of Timing, Efficacy, and Specificity
The transcriptional profile of microglia is significantly altered after spinal cord injury (SCI). When choosing a marker to label microglia after SCI, it is important to consider its specificity for microglia and its stability of expression. ABSTRACT Traumatic spinal cord injury (SCI) is a complex and disabling condition with no curative therapy ...
Ruth Colbert +2 more
wiley +1 more source
BCMA Antigen Loss Through Acquired TNFRSF17 Deletion in Multiple Myeloma
International Journal of Laboratory Hematology, EarlyView.
Ali Benaboud +5 more
wiley +1 more source
Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape. [PDF]
Roccatello D +3 more
europepmc +1 more source
mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia. [PDF]
Lu Y +13 more
europepmc +1 more source
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon +2 more
wiley +1 more source
Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction. [PDF]
Dos Anjos AS +8 more
europepmc +1 more source
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera +24 more
wiley +1 more source

